Xeltis secures additional funding to finalise US pivotal trial of aXess vascular access conduit
Xeltis has announced an additional €20.5m of new funding from new and existing shareholders, with the proceeds to be used to finalise the ongoing...
US FDA approves Fabhalta to slow kidney function decline in primary IgAN
Novartis has announced that the US Food and Drug Administration (FDA) has granted traditional approval for Fabhalta (iptacopan) to slow kidney function decline in...
Nephrologists join Humacyte in advisory role
Humacyte has announced that Robert J Kossmann (Fresenius Medical Care, Waltham, USA) and Prabir Roy-Chaudhury (University of North Carolina, Chapel Hill, USA) have joined...
VOICE trial of Vafseo for dialysis patients ends following positive interim data
Akebia Therapeutics and US Renal Care (USRC) have announced the decision by USRC Kidney Research to stop the Vafseo Outcomes In Center Experience—VOICE—trial following...
